Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study.
The pharmacokinetics of acebutolol and its major metabolite, diacetolol, following a single 400 mg oral dose, were investigated in patients with liver disease. No significant differences were found in any of the parameters measured.